TABLE 1.
Patient characteristics at baselinea
| Characteristic | Value(s) for the following study(ies): |
|||||
|---|---|---|---|---|---|---|
| Tarning and colleagues (21, 24) | Jullien et al. (23) | Mwesigwa et al. (25) | Stepniewska et al. (22) | Adjei et al. (20) | Total | |
| No. of patients | 26 (+7)b | 53 | 20 | 61 | 101 | 261 |
| % of male patients (no. of male patients/total no. of patients) | 0 (0/26) | 47.2 (25/53) | 65.0 (13/20) | 54.1 (33/61) | 50.5 (51/101) | 46.7 (122/261) |
| Median (range) age (yr) | 23.0 (16.0–39.0) | 24.0 (18.0–60.0) | 9.0 (6.0–13.0) | 2.5 (1.0–5.0) | 6.0 (1.0–14.0) | 7.6 (1.0–60.0) |
| % of patients aged (yr) (no. of patients of the indicated age/total no. of patients): | ||||||
| <2 | 0 (0/26) | 0 (0/53) | 0 (0/20) | 32.8 (20/61) | 12.9 (13/101) | 12.6 (33/261) |
| 2 to <5 | 0 (0/26) | 0 (0/53) | 0 (0/20) | 65.6 (40/61) | 21.8 (22/101) | 23.8 (62/261) |
| 5 to <12 | 0 (0/26) | 0 (0/53) | 90.0 (18/20) | 1.6 (1/61) | 53.5 (54/101) | 28.0 (73/261) |
| 12+ | 100 (26/26) | 100 (53/53) | 10.0 (2/20) | 0 (0/61) | 11.9 (12/101) | 34.6 (93/261) |
| % of patients receiving the following drug formulation, treatment regimen (no. of patients receiving the formulation, regimen/total no.): | ||||||
| AQ + AS, FDC | 0 (0/26) | 47 (25/53) | 0 (0/20) | 47.5 (29/61) | 0 (0/101) | 20.7 (54/261) |
| AQ + AS, separate tablets | 0 (0/26) | 53 (28/53) | 100 (20/20) | 52.5 (32/61) | 85.2 (86/101) | 63.6 (166/261) |
| AQ alone | 100 (26/26) | 0 (0/53) | 0 (0/20) | 0 (0/61) | 14.8 (15/101) | 15.7 (41/261) |
| Enrollment demographic, vital, and laboratory parameters | ||||||
| Median (range) wt (kg) | 49.0 (37.0–68.0) | 59.0 (39.0–90.0) | 24.5 (20.0–42.0) | 12.5 (7.0–31.0) | 18.0 (6.5–93.0) | 21.0 (6.5–93.0) |
| Median (range) total dose (mg/kg) | 30.5 (28.1–63.0) | 29.5 (18.0–47.1) | 24.3 (23.9–26.0) | 33.7 (14.8–65.6) | 30.0 (30.0–30.0) | 30.0 (14.8–65.6) |
| Geometric mean (range) parasitemia (no. of parasites/μl) | 1,142 (96–50,453)c | 11,923 (1,127–109,356) | 11,122 (240–174,800) | 23,110 (1,357–467,600) | 42,689 (630–566,358) | 17,952 (96–566,358) |
| Median (range) hematocrit (%) | 32.5 (23.0–40.0) | 32.5 (23.0–40.0) | ||||
| Median (range) hemoglobin concn (g/dl) | 10.3 (6.7–13.2)d | 13.2 (9.9–17.7) | 12.2 (9.7–14.1) | 8.7 (5.9–12.4) | 11.6 (6.5–15.1) | 11.2 (5.9–17.7) |
a
Percentages can be more than 100% due to rounding errors. AQ, amodiaquine; AS, artesunate; FDC, fixed-dose combination.
b
Seven patients were sampled again after delivery, during another episode of malaria.
c
The data are for patients with vivax malaria.
d
Derived on the basis of their hematocrit value.